Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

Arcutis Biotherapeutics, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

WESTLAKE VILLAGE, CALIF., JULY 16, 2026 (GLOBE NEWSWIRE) -- ARCUTIS BIOTHERAPEUTICS, INC. (NASDAQ: ARQT), A COMMERCIAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING MEANINGFUL INNOVATION IN IMMUNO-DERMATOLOGY, TODAY ANNOUNCED THAT CHRISTOPHER CHRIS PEETZ HAS BEEN APPOINTED TO THE ARCUTIS BOARD OF DIRECTORS EFFECTIVE JULY 15, 2026.

ARCUTIS EXPANDS BOARD OF DIRECTORS WITH APPOINTMENT OF CHRIS PEETZ

WESTLAKE VILLAGE, CALIF., JULY 15, 2026 (GLOBE NEWSWIRE) -- ARCUTIS BIOTHERAPEUTICS, INC. (NASDAQ: ARQT), A COMMERCIAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING MEANINGFUL INNOVATIONS IN IMMUNO-DERMATOLOGY, TODAY ANNOUNCED THAT IT WILL REPORT ITS SECOND QUARTER 2026 FINANCIAL RESULTS AND PROVIDE A BUSINESS UPDATE AFTER THE U.S. FINANCIAL MARKETS CLOSE ON WEDNESDAY, AUGUST 5, 2026.

ARCUTIS TO REPORT SECOND QUARTER 2026 FINANCIAL RESULTS AND HOST CONFERENCE CALL ON AUGUST 5, 2026

FDA HAS SET A PRESCRIPTION DRUG USER FEE ACT (PDUFA) TARGET ACTION DATE OF FEBRUARY 23, 2027 APPLICATION SUPPORTED BY POSITIVE RESULTS FROM PHASE 2 OPEN-LABEL INTEGUMENT-INFANT STUDY AND PHASE 1 OPEN-LABEL PHARMACOKINETIC (PK) STUDY 1 MILLION CHILDREN UNDER THE AGE OF 2 ARE TREATED TOPICALLY FOR ATOPIC DERMATITIS IN THE UNITED STATES, REPRESENTING 10% OF ALL ADULTS AND CHILDREN TREATED TOPICALLY FOR ATOPIC DERMATITIS WESTLAKE VILLAGE, CALIF., JULY 08, 2026 (GLOBE NEWSWIRE) -- ARCUTIS BIOTHERAPEUTICS, INC. (NASDAQ: ARQT), A COMMERCIAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING MEANINGFUL INNOVATIONS IN IMMUNO-DERMATOLOGY, TODAY ANNOUNCED THAT THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) HAS ACCEPTED ITS SUPPLEMENTAL NEW DRUG APPLICATION (SNDA) FORZORYVE (ROFLUMILAST) CREAM 0.05% TO EXPAND THE INDICATION FOR THE TOPICAL TREATMENT OF MILD TO MODERATE ATOPIC DERMATITIS TO INCLUDE INFANTS AGED 3 TO 24 MONTHS.

FDA ACCEPTS SUPPLEMENTAL NEW DRUG APPLICATION FOR ARCUTIS' ZORYVE (ROFLUMILAST) CREAM 0.05% FOR THE TREATMENT OF MILD TO MODERATE ATOPIC DERMATITIS IN INFANTS DOWN TO 3 MONTHS

WESTLAKE VILLAGE, CALIF., JULY 02, 2026 (GLOBE NEWSWIRE) -- ARCUTIS BIOTHERAPEUTICS, INC. (NASDAQ: ARQT), A COMMERCIAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING MEANINGFUL INNOVATIONS IN IMMUNO-DERMATOLOGY, TODAY ANNOUNCED THE GRANT OF AN AGGREGATE OF 61,000 RESTRICTED STOCK UNITS (RSUS) OF ARCUTIS COMMON STOCK TO 9 NEWLY HIRED EMPLOYEES. THESE AWARDS WERE APPROVED BY THE COMPENSATION COMMITTEE OF ARCUTIS' BOARD OF DIRECTORS AND GRANTED UNDER THE ARCUTIS BIOTHERAPEUTICS, INC. 2022 INDUCEMENT PLAN, WITH A GRANT DATE OF JULY 1, 2026, AS A MATERIAL INDUCEMENT TO THE NEW EMPLOYEES IN CONNECTION WITH THEIR COMMENCEMENT OF EMPLOYMENT WITH ARCUTIS, IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).

ARCUTIS BIOTHERAPEUTICS REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

VIRTUAL HEALTH PLATFORM OFFERS AN ADDITIONAL PATHWAY TO CARE FOR THE MORE THAN 45 MILLION PEOPLE IN THE U.S. LIVING WITH ECZEMA, SEBORRHEIC DERMATITIS, AND PLAQUE PSORIASIS CONNECTS ELIGIBLE INDIVIDUALS WITH INDEPENDENT, BOARD-CERTIFIED DERMATOLOGISTS THROUGH A STREAMLINED DIGITAL EXPERIENCE FOR EVALUATION AND TO DISCUSS POTENTIAL TREATMENT OPTIONS WESTLAKE VILLAGE, CALIF., JUNE 30, 2026 (GLOBE NEWSWIRE) -- ARCUTIS BIOTHERAPEUTICS, INC. (NASDAQ: ARQT), A COMMERCIAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING MEANINGFUL INNOVATIONS IN IMMUNO-DERMATOLOGY, TODAY ANNOUNCED THE LAUNCH OF A NEW VIRTUAL HEALTH PLATFORM DESIGNED TO EXPAND ACCESS PATHWAYS TO ITS ZORYVE (ROFLUMILAST) PORTFOLIO FOR CHRONIC INFLAMMATORY SKIN DISEASES.

ARCUTIS LAUNCHES NEW VIRTUAL HEALTH PLATFORM SUPPORTING ACCESS TO CARE FOR INDIVIDUALS LIVING WITH CHRONIC INFLAMMATORY SKIN DISEASES, INCLUDING APPROVED ZORYVE (ROFLUMILAST) INDICATIONS

ZORYVE CREAM 0.3% IS THE FIRST ONCE-DAILY, NON-STEROIDAL THERAPY APPROVED FOR CHILDREN WITH PLAQUE PSORIASIS AS YOUNG AS 2 YEARS OF AGE ZORYVE CREAM 0.3% IS SAFE, EFFECTIVE, AND WELL-TOLERATED FOR USE ANYWHERE ON THE BODY WITH NO RESTRICTIONS ON DURATION OF USE SEVENTH FDA APPROVAL FOR ZORYVE IN FOUR YEARS WESTLAKE VILLAGE, CALIF., JUNE 29, 2026 (GLOBE NEWSWIRE) -- ARCUTIS BIOTHERAPEUTICS, INC. (NASDAQ: ARQT), A COMMERCIAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING MEANINGFUL INNOVATIONS IN IMMUNO-DERMATOLOGY, TODAY ANNOUNCED THAT THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) HAS APPROVED THE SUPPLEMENTAL NEW DRUG APPLICATION (SNDA) TO EXPAND THE INDICATION FOR ZORYVE (ROFLUMILAST) CREAM 0.3% FOR THE TOPICAL TREATMENT OF PLAQUE PSORIASIS, INCLUDING INTERTRIGINOUS AREAS, TO CHILDREN DOWN TO AGE 2.

FDA APPROVES ARCUTIS' ZORYVE (ROFLUMILAST) CREAM 0.3% FOR THE TREATMENT OF PLAQUE PSORIASIS IN CHILDREN AS YOUNG AS AGE 2

WESTLAKE VILLAGE, CALIF., JUNE 05, 2026 (GLOBE NEWSWIRE) -- ARCUTIS BIOTHERAPEUTICS, INC. (NASDAQ: ARQT), A COMMERCIAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING MEANINGFUL INNOVATIONS IN IMMUNO-DERMATOLOGY, TODAY REPORTED THE GRANT OF AN AGGREGATE OF 44,000 RESTRICTED STOCK UNITS OF ARCUTIS' COMMON STOCK TO SIX NEWLY HIRED EMPLOYEES. THESE AWARDS WERE APPROVED BY THE COMPENSATION COMMITTEE OF ARCUTIS' BOARD OF DIRECTORS AND GRANTED UNDER THE ARCUTIS BIOTHERAPEUTICS, INC. 2022 INDUCEMENT PLAN, WITH A GRANT DATE OF JUNE 1, 2026, AS A MATERIAL INDUCEMENT TO THE NEW EMPLOYEES ENTERING INTO EMPLOYMENT WITH ARCUTIS, IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).

EXPERT RECOMMENDATIONS FOCUSED ON THE DIAGNOSIS AND MANAGEMENT OF GENITAL PSORIASIS ACROSS AGE GROUPS INCLUDING PEDIATRIC, ADULT, AND OLDER POPULATIONS THIS IS THE SECOND PUBLISHED MANUSCRIPT FROM THE GENITAL PSORIASIS WELLNESS CONSORTIUM, A MULTIDISCIPLINARY GROUP OF EXPERT CLINICIANS GENITAL INVOLVEMENT OCCURS IN APPROXIMATELY TWO-THIRDS OF THE NINE MILLION INDIVIDUALS WITH PLAQUE PSORIASIS IN THE UNITED STATES WESTLAKE VILLAGE, CALIF., JUNE 03, 2026 (GLOBE NEWSWIRE) -- ARCUTIS BIOTHERAPEUTICS, INC. (NASDAQ: ARQT), A COMMERCIAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING MEANINGFUL INNOVATIONS IN IMMUNO-DERMATOLOGY, TODAY ANNOUNCED THE PUBLICATION OF A NEW MANUSCRIPT IN THE AMERICAN JOURNAL OF CLINICAL DERMATOLOGY BY THE GENITAL PSORIASIS WELLNESS CONSORTIUM.

NEW EXPERT CONSENSUS PROVIDES AGE-SPECIFIC GUIDANCE FOR IMPROVING CARE FOR INDIVIDUALS WITH GENITAL PSORIASIS PUBLISHED IN THE AMERICAN JOURNAL OF CLINICAL DERMATOLOGY

ARCUTIS TODAY ANNOUNCED THAT MANAGEMENT WILL PRESENT AT THE GOLDMAN SACHS 47TH ANNUAL GLOBAL HEALTHCARE CONFERENCE, TAKING PLACE JUNE 8-10, 2026, IN MIAMI.

ARCUTIS MANAGEMENT TO PRESENT AT GOLDMAN SACHS 47TH ANNUAL GLOBAL HEALTHCARE CONFERENCE

WESTLAKE VILLAGE, CALIF., MAY 08, 2026 (GLOBE NEWSWIRE) -- ARCUTIS BIOTHERAPEUTICS, INC. (NASDAQ: ARQT), A COMMERCIAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING MEANINGFUL INNOVATIONS IN IMMUNO-DERMATOLOGY, TODAY REPORTED THE GRANT OF AN AGGREGATE OF 269,000 RESTRICTED STOCK UNITS OF ARCUTIS' COMMON STOCK AS WELL AS OPTIONS TO PURCHASE AN AGGREGATE OF 70,000 SHARES OF ARCUTIS' COMMON STOCK TO 40 NEWLY HIRED EMPLOYEES. THESE AWARDS WERE APPROVED BY THE COMPENSATION COMMITTEE OF ARCUTIS' BOARD OF DIRECTORS AND GRANTED UNDER THE ARCUTIS BIOTHERAPEUTICS, INC. 2022 INDUCEMENT PLAN, WITH A GRANT DATE OF MAY 1, 2026, AS AN INDUCEMENT MATERIAL TO THE NEW EMPLOYEES ENTERING INTO EMPLOYMENT WITH ARCUTIS, IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).

Arcutis Biotherapeutics, Inc.

ARQT

Price

Financial Reports

No items found.

Press Releases

Arcutis Biotherapeutics, Inc.

ARQT.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

ARQT